Norditropin Nordiflex (Somatropin)

Somatropin mimics natural human growth hormone by binding to growth hormone receptors, triggering the JAK2‑STAT5 pathway, which increases IGF‑1 production. This cascade promotes protein synthesis, cell proliferation, and linear growth in children, while improving metabolism in adults.

The dose of Norditropin Nordiflex is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, clinical condition, and IGF‑1 response, following established treatment guidelines.

Safety data for somatropin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the prescribing physician.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Norditropin Nordiflex is a recombinant human growth hormone formulated in a pre‑filled pen for easy subcutaneous administration. Compared with vial‑based products, it offers convenience, dose accuracy, and reduced preparation time, while delivering the same active molecule as other approved somatropin brands.

The product must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. If needed for short periods, it may be kept at room temperature (up to 25 °C) for a maximum of 28 days, as specified in the product labeling.

Norditropin Nordiflex is delivered via subcutaneous injection using the pre‑filled pen. The patient or caregiver selects the prescribed dose, inserts the pen needle, and injects into a fatty tissue area such as the abdomen, thigh, or upper arm, following aseptic technique.

Serious risks include intracranial hypertension, slipped epiphysis in growing children, severe allergic reactions, and disturbances in glucose metabolism that may precipitate diabetes. Patients should be monitored regularly for these complications.

Norditropin Nordiflex is contraindicated in patients with active malignancy, known hypersensitivity to somatropin or any excipients, and those with acute critical illness due to systemic inflammation. It should also be avoided in individuals with uncontrolled diabetes until the condition is stabilized.